1. Home
  2. RILY vs ZNTL Comparison

RILY vs ZNTL Comparison

Compare RILY & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RILY
  • ZNTL
  • Stock Information
  • Founded
  • RILY 1973
  • ZNTL 2014
  • Country
  • RILY United States
  • ZNTL United States
  • Employees
  • RILY N/A
  • ZNTL N/A
  • Industry
  • RILY Investment Managers
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • RILY Finance
  • ZNTL Health Care
  • Exchange
  • RILY Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • RILY 142.1M
  • ZNTL 136.8M
  • IPO Year
  • RILY 2007
  • ZNTL 2020
  • Fundamental
  • Price
  • RILY $4.37
  • ZNTL $1.84
  • Analyst Decision
  • RILY
  • ZNTL Buy
  • Analyst Count
  • RILY 0
  • ZNTL 8
  • Target Price
  • RILY N/A
  • ZNTL $8.53
  • AVG Volume (30 Days)
  • RILY 4.5M
  • ZNTL 997.5K
  • Earning Date
  • RILY 03-17-2025
  • ZNTL 05-06-2025
  • Dividend Yield
  • RILY 11.55%
  • ZNTL N/A
  • EPS Growth
  • RILY N/A
  • ZNTL N/A
  • EPS
  • RILY N/A
  • ZNTL N/A
  • Revenue
  • RILY $854,383,000.00
  • ZNTL $40,560,000.00
  • Revenue This Year
  • RILY N/A
  • ZNTL N/A
  • Revenue Next Year
  • RILY N/A
  • ZNTL N/A
  • P/E Ratio
  • RILY N/A
  • ZNTL N/A
  • Revenue Growth
  • RILY N/A
  • ZNTL N/A
  • 52 Week Low
  • RILY $2.73
  • ZNTL $1.61
  • 52 Week High
  • RILY $40.09
  • ZNTL $16.27
  • Technical
  • Relative Strength Index (RSI)
  • RILY 45.82
  • ZNTL 38.71
  • Support Level
  • RILY $4.70
  • ZNTL $1.79
  • Resistance Level
  • RILY $5.82
  • ZNTL $2.01
  • Average True Range (ATR)
  • RILY 1.07
  • ZNTL 0.20
  • MACD
  • RILY -0.04
  • ZNTL -0.02
  • Stochastic Oscillator
  • RILY 36.61
  • ZNTL 14.97

About RILY B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Share on Social Networks: